Takeda Pharma Cash Flow - Quarterly (OTCMKTS:TKPYY)

Add to My Stocks
$21.16 $0.18 (0.86%) TKPYY stock closing price Sep 20, 2018 (Closing)

The Takeda Pharma cash flow statement helps investors understand how well the company is managing its cash flows. While its important to look at the Takeda Pharma debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Takeda Pharma revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Takeda Pharma saw a cash impact of $- from the buyback of TKPYY shares. The cash flow statement helps in the Takeda Pharma stock analysis by providing more information for evaluating changes in assets, liabilities and equities. TKPYY decrease in investments stood at a value of $- for the latest quarter 2018 Q1.

View and download details of Takeda Pharma cash flows for latest & last 40 quarters
show more
Fiscal year is Apr - Mar2018 Q12017 Q42017 Q12016 Q4
Net Income Cash Flow
-1.07B-692.88M
Depreciation Depletion Amortization Cash-Flow-2.07B-1.64B
Net Increase (Decrease) in Assets Liabilities-513.03M--2.03B
Cash From (used in) Discontinued Operations----
Other Adjustments Net--1.23B--85.09M
Net Cash from (used by) Operating Activities
-2.43B-211.57M
Increase (Decrease) in Prop Plant And Equipment--545.51M--400.3M
Acquisition Disposition of Subsidiaires--4.88B--58.53M
Increase (Decrease) in Investments--63.59M-136.42M
Other Cash Inflow (Outflow) from Investment Activities--608.73M--268.62M
Net Cash from (used by) Investment Activities
--6.1B--591.02M
Issuance (Purchase) of Equity Shares--214.98M--185.47M
Issuance (Repayment) of Debt Securities-636.7M-414.9M
Increase (Decrease) in Bank & Other Borrowings-3.78B--0.04M
Payment of Dividends & Other Cash Distributions--1.32B--1.17B
Other Cash from (used by) Financing Activities--192.81M--90.77M
Net Cash from (used by) Financing Activities
-2.7B--1.04B
Effect of Exchange Rate Changes on Cash--256.12M--276.05M
Net Change in Cash & Cash Equivalents
--1.23B--1.69B
Cash & Equivalents at Beginning of Year6.06B5.46B10.27B8.15B
Cash & Equivalents at Year End-2.97B-3.75B
All figures in USD. M: Millions of USD, B: Billions of USD.

Takeda Pharma stock price history provides insight into historical stock price fluctuations, and Takeda Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Takeda Pharma saw a positive change in Net Change in Cash and Cash Equivalents of $- till 2018 Q1. Apart from the Takeda Pharma stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Takeda Pharma lost $- cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $- for TKPYY till last quarter 2018 Q1 report.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Takeda Pharma spent $- from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Takeda Pharma Cash Flow

FCF margin
0

Quarterly Cash Flow Statements For Takeda Pharmaceutical Co Ltd (ADR) Peers

Astellas Pharma cash flow, Celgene cash flow, ImmunoGen cash flow, Teva Pharmaceutical cash flow, Zoetis cash flow